Research Analysts Offer Predictions for Exelixis Q4 Earnings

Key Points

• Zacks Research has decreased its Q4 2025 earnings estimate for Exelixis to $0.55 per share, down from $0.56, while maintaining a "Hold" rating on the stock.
• During the last quarterly earnings report, Exelixis reported earnings of $0.75 per share, exceeding expectations, but revenue was down by 10.8% compared to the previous year.
• Thirteen investment analysts have rated Exelixis with a Buy rating, and one analyst issued a Sell rating, reflecting a consensus rating of "Moderate Buy" with an average price target of $44.06.

Exelixis, Inc. (NASDAQ:EXEL - Free Report) - Investment analysts at Zacks Research cut their Q4 2025 EPS estimates for shares of Exelixis in a research report issued on Wednesday, August 27th. Zacks Research analyst Team now anticipates that the biotechnology company will earn $0.55 per share for the quarter, down from their prior estimate of $0.56. Zacks Research currently has a "Hold" rating on the stock. The consensus estimate for Exelixis' current full-year earnings is $2.04 per share. Zacks Research also issued estimates for Exelixis' Q4 2026 earnings at $0.75 EPS.

Exelixis (NASDAQ:EXEL - Get Free Report) last issued its earnings results on Monday, July 28th. The biotechnology company reported $0.75 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.63 by $0.12. Exelixis had a net margin of 27.01% and a return on equity of 27.47%. The business had revenue of $568.26 million for the quarter, compared to analysts' expectations of $574.36 million. During the same quarter in the previous year, the firm posted $0.84 EPS. The business's revenue for the quarter was down 10.8% compared to the same quarter last year. Exelixis has set its FY 2025 guidance at EPS.

A number of other equities research analysts also recently issued reports on the stock. Stifel Nicolaus increased their price target on shares of Exelixis from $38.00 to $41.00 and gave the stock a "hold" rating in a report on Tuesday, July 29th. William Blair reiterated an "outperform" rating on shares of Exelixis in a research note on Tuesday, July 29th. HC Wainwright reduced their price target on shares of Exelixis from $53.00 to $46.00 and set a "buy" rating for the company in a research report on Tuesday, August 12th. Barclays increased their price objective on Exelixis from $29.00 to $40.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 10th. Finally, Morgan Stanley reduced their target price on Exelixis from $48.00 to $46.00 and set an "overweight" rating for the company in a research report on Tuesday, July 29th. Thirteen research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Exelixis currently has a consensus rating of "Moderate Buy" and a consensus target price of $44.06.

Exelixis Stock Down 1.3%

EXEL traded down $0.48 during trading on Friday, reaching $37.42. 2,589,106 shares of the company were exchanged, compared to its average volume of 2,502,768. Exelixis has a 12-month low of $25.12 and a 12-month high of $49.62. The company's 50-day moving average is $41.26 and its two-hundred day moving average is $39.53. The company has a market cap of $10.07 billion, a price-to-earnings ratio of 17.99, a P/E/G ratio of 0.77 and a beta of 0.32.

Institutional Investors Weigh In On Exelixis

Institutional investors have recently bought and sold shares of the stock. Hemington Wealth Management lifted its position in Exelixis by 211.3% in the first quarter. Hemington Wealth Management now owns 769 shares of the biotechnology company's stock valued at $28,000 after purchasing an additional 522 shares during the last quarter. Colonial Trust Co SC raised its holdings in Exelixis by 616.9% during the 4th quarter. Colonial Trust Co SC now owns 889 shares of the biotechnology company's stock valued at $30,000 after buying an additional 765 shares during the last quarter. Byrne Asset Management LLC raised its holdings in Exelixis by 129.0% during the 2nd quarter. Byrne Asset Management LLC now owns 710 shares of the biotechnology company's stock valued at $31,000 after buying an additional 400 shares during the last quarter. Luminist Capital LLC boosted its position in Exelixis by 2,740.0% during the 2nd quarter. Luminist Capital LLC now owns 710 shares of the biotechnology company's stock valued at $31,000 after buying an additional 685 shares during the period. Finally, Family Legacy Financial Solutions LLC bought a new stake in Exelixis in the 2nd quarter worth $33,000. 85.27% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, Director Sue Gail Eckhardt sold 18,838 shares of the stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $42.74, for a total transaction of $805,136.12. Following the transaction, the director owned 21,380 shares of the company's stock, valued at approximately $913,781.20. This trade represents a 46.84% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jack L. Wyszomierski sold 7,535 shares of the business's stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $43.09, for a total transaction of $324,683.15. Following the completion of the sale, the director directly owned 358,882 shares of the company's stock, valued at $15,464,225.38. This represents a 2.06% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 2.85% of the company's stock.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.